Company Overview and News

24
50 Top Technology Dividend WallStars By Yield And Gains For October

12h seekingalpha
WallStars all show positive broker target price upsides. Top WallStar Technology ten by net gains, STX, XRX, KLAC, CY, LRCX, RELL, CAMT, WDC, TIVO and XPER, averaged 61.15%, calculated 10/15/18.
LRCX CY XPER RELLB WDC STX KLAC XRX CAMT LYTS UMC NOK RELL TESS TIVO

1
LYTS / LSI Industries, Inc. FORM 8-K (Current Report)

12h sec.gov - 1
lyts20181016_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LYTS

 
LYTS / LSI Industries, Inc. FORM DEF 14A

2018-09-28 sec.gov
lyts20180924_def14a.htm SCHEDULE 14A (Rule 14a-101)
LYTS

29
50 Top Technology Dividend WallStars By Yield And Gains For September

2018-09-14 seekingalpha - 1
WallStars show positive broker target price upsides. Top WallStar Technology ten by broker estimated net gains, XRX, CY, DAKT, CAMT, RELL, LRCX, TIVO, LYTS, WDC, & XPER, averaged 52.39%, calculated.
LRCX CY XPER RELLB WDC STX XRX DAKT CAMT LYTS UMC NOK RELL QCOM TESS TIVO

1
LYTS / LSI Industries, Inc. FORM 10-K (Annual Report)

2018-09-11 sec.gov - 1
lyts20180630_10k.htm
LYTS

1
LYTS / LSI Industries, Inc. null (Current Report)

2018-08-21 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LYTS

 
LSI Industries Inc (LYTS) CEO Ron Brown on Q4 2018 Results - Earnings Call Transcript

2018-08-16 seekingalpha
LSI Industries Inc. (NASDAQ:LYTS) Q4 2018 Results Earnings Conference Call August 16, 2018 10:00 AM ET
LYTS

 
LYTS / LSI Industries, Inc. null (Current Report)

2018-08-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 LYTS

6
LSI Industries Inc. Appoints Wilfred (Bill) T. O’Gara as Chairman, Board of Directors; Implements Key Organization Structure/Leadership Changes

2018-08-16 globenewswire
CINCINNATI, Aug. 16, 2018 (GLOBE NEWSWIRE) -- LSI Industries Inc. (NASDAQ:LYTS) today announced that Wilfred (Bill) T. O’Gara has been appointed Chairman of the Board by the Board of Directors, succeeding Gary P. Kreider, who has served as Chairman of the Board since November, 2014. Mr. Kreider will remain a board member until a successor director is appointed, at which time Mr. Kreider intends to retire from the board.
LYTS AYI AYI.WI

 
LSI Industries Inc. Reports Operating Results for the Fourth Quarter and Full Year Ended June 30, 2018; Declares Regular Cash Dividend

2018-08-16 globenewswire
Net sales in the fourth quarter of fiscal 2018 were $83,409,000, flat compared to the $83,419,000 reported in the same period of the prior year. Reported net income was a loss of $(2,664,000) compared to net income of $696,000 in the fourth quarter 2017. Reported EPS of $(0.10) was below reported EPS of $0.03 for the fourth quarter of the prior year. The business recorded a fourth quarter charge of $3,136,000 related to the CEO transition announced earlier in the quarter.
LYTS

8
Acuity Brands Gains on Innovation, Higher Costs Hurt

2018-08-15 zacks
Acuity Brands, Inc.’s (AYI - Free Report) innovative lighting control solutions and energy-efficient luminaries are substantial growth drivers. However, higher material costs, along with research and development expenses might hamper its margins. Key Growth Drivers Product Innovation: Acuity Brands is continually expanding its portfolio of innovative lighting control solutions and energy-efficient luminaries to drive growth.
OESX AYI LYTS EFOI AYI.WI

 
LSI Industries Inc. Schedules Conference Call to Discuss Fourth Quarter Fiscal 2018 Results and Provide an Update on Future Plans

2018-07-27 globenewswire
CINCINNATI, July 27, 2018 (GLOBE NEWSWIRE) -- LSI Industries Inc. (NASDAQ:LYTS) today announced that the Company will host a conference call to discuss fourth quarter fiscal 2018 results on August 16, 2018 at 10:00 a.m. EDT. Management will also provide an update on the status of current and future actions to strengthen the Company during the call. A press release covering both the earnings announcement and future plans will be issued prior to market open that same day.
LYTS

 
LSI Industries Inc. Announces Lighting Leadership Change and Comments on Future Plans

2018-07-10 globenewswire
CINCINNATI, July 10, 2018 (GLOBE NEWSWIRE) -- LSI Industries Inc. (NASDAQ:LYTS) today announced that Ron Newbold, President of LSI Lighting, has decided to leave the company for personal reasons. Effective immediately Chief Operating Officer, Crawford Lipsey, will assume direct responsibility for the Lighting Leadership team.
LYTS

 
LYTS / LSI Industries, Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us50216c1080_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) LSI INDUSTRIES INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 50216C108 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pag
LYTS

1
LYTS / LSI Industries, Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov - 1
us50216c1080_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) LSI INDUSTRIES INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 50216C108 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pag
LYTS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to LYTS / LSI Industries, Inc. on message board site Silicon Investor.

LYTS - LSI Inds Inc LYTS - LSI Inds Inc LYTS - LSI Inds Inc
CUSIP: 50216C108